"""
Question: 1101

Evidence: A retrospective study was carried out in which baseline and on-therapy presence of drug resistance mutations in the HIV-1 protease and reverse tran- scriptase genes were analysed in patients with PLLV between 20 and 250 copies/ml. For all available plasma samples collected during PLLV, resistance analysis was attempted with an ultrasensitive amplification and sequencing protocol.

Rationale: The paper describes a study that was conducted, including its methods and results, which implies the data being presented is from their own research and analysis, not a review of previously published data.

Answer: Yes
"""

"""
Question: 1102

Evidence: For all available plasma samples collected during PLLV, resistance analysis was attempted with an ultrasensitive amplification and sequencing protocol. Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA) and sequences were analysed using SmartGene (IDNS™) software (SmartGene GmbH, Zug, Switzerland).

Rationale: The paper explicitly describes sequencing the HIV-1 protease and reverse transcriptase genes from patient plasma samples as part of their resistance analysis.

Answer: Yes
"""

"""
Question: 1103

Evidence: The paper does not contain any mention of in vitro passage experiments.

Rationale: A thorough reading of the abstract, introduction, methods, results, and discussion sections reveals no description of in vitro passage experiments. The study is focused on clinical samples from patients.

Answer: No
"""

"""
Question: 1104

Evidence: The paper does not contain any mention of in vitro antiretroviral susceptibility testing or data.

Rationale: The methods section details sequencing for genotypic resistance analysis but does not mention phenotypic susceptibility assays. The results and discussion sections refer to mutations and predicted susceptibility based on genotypic data (e.g., "only one of the detected mutations decreased susceptibil- ity to the therapy regimen"), not measured IC50 values or other phenotypic data.

Answer: No
"""

"""
Question: 2101

Evidence: The paper does not contain any GenBank accession numbers.

Rationale: A search through the entire paper text, including the acknowledgements and disclosure sections, finds no mention of GenBank or accession numbers.

Answer: No
"""

"""
Question: 2102

Evidence: The paper does not contain any GenBank accession numbers.

Rationale: Since no GenBank accession numbers are reported at all, there are none for laboratory isolates or any other type of isolate.

Answer: No
"""

"""
Question: 2103

Evidence: The paper does not contain any GenBank accession numbers.

Rationale: No GenBank accession numbers are mentioned in any section of the paper.

Answer: NA
"""

"""
Question: 2202

Evidence: Historical DRMs, detected before study initiation, were observed in three patients. Patient 13 was infected with an NRTI-resistant strain (mutations D67N, T69D and T215C)... In patients 12 and 14, M184V and M184I+Y188C (respectively) had been selected by previous regimens... New DRM, not present at study initiation or in earlier samples, were found in four isolated samples from four different patients: K101E in patient 1... Y188C in patient 13... I50L in patient 19... and K219E in patient 21.

Rationale: The paper provides specific lists of mutations (e.g., D67N, T69D, T215C; M184V; K101E) that were identified in individual patients, as detailed in the Results section.

Answer: Yes
"""

"""
Question: 2301

Evidence: These 23 patients were all male with a median age of 48 years (IQR 43–54 years). All except one were infected with a subtype B HIV-1.

Rationale: The paper states that the patients were infected with HIV-1, specifying the subtype for most. No other HIV species (e.g., HIV-2) are mentioned.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: All except one were infected with a subtype B HIV-1.

Rationale: This sentence directly states the subtype of the viruses sequenced for the vast majority of the study participants.

Answer: Subtype B
"""

"""
Question: 2303

Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol [16]. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples.

Rationale: The methods section explicitly states that the HIV-1 protease (PR) and reverse transcriptase (RT) genes were sequenced.

Answer: Protease and Reverse Transcriptase
"""

"""
Question: 2304

Evidence: Resistance mutations in PR-RT were assessed... An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples.

Rationale: The paper consistently reports on the sequencing of the pol gene region encompassing protease and reverse transcriptase (PR-RT).

Answer: Yes
"""

"""
Question: 2401

Evidence: Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients followed at the Ghent University Hospital.

Rationale: The study population was selected from a single hospital in Ghent, which is in Belgium.

Answer: Belgium
"""

"""
Question: 2402

Evidence: ...all samples collected until study closure (February 2014)... Follow-up started 6 months after antiretroviral therapy (ART) initiation and ended at virological failure or study closure (February 2014).

Rationale: The paper states the study closure date (February 2014) and that samples were collected from 6 months post-ART initiation until that date. The exact start years for individual patients are not provided, but the collection period ended in February 2014.

Answer: Samples were collected until February 2014. Specific start years are not provided.
"""

"""
Question: 2502

Evidence: Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA) and sequences were analysed using SmartGene (IDNS™) software (SmartGene GmbH, Zug, Switzerland).

Rationale: The ABI3130 is a capillary electrophoresis sequencer used for Sanger sequencing. The description of analyzing sequences and identifying mixtures based on peak heights is characteristic of Sanger sequencing.

Answer: Yes
"""

"""
Question: 2503

Evidence: The paper does not mention Next Generation Sequencing (NGS) or any related technologies.

Rationale: The sequencing methodology described (ABI3130 Sequencer, analysis of peak heights) is exclusively for Sanger sequencing. No NGS platforms or terminologies are used.

Answer: No
"""

"""
Question: 2504

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The methods section describes an ultrasensitive PCR and sequencing protocol but does not include any steps for molecular cloning.

Answer: No
"""

"""
Question: 2505

Evidence: The paper does not mention single genome sequencing or SGS.

Rationale: The sequencing protocol is described as a bulk PCR amplification, not a method designed to amplify from a single genome template.

Answer: No
"""

"""
Question: 2506

Evidence: The paper does not mention molecular cloning.

Rationale: The methods section details the amplification and sequencing process without any reference to cloning steps.

Answer: No
"""

"""
Question: 2601

Evidence: For all available plasma samples collected during PLLV, resistance analysis was attempted with an ultrasensitive amplification and sequencing protocol.

Rationale: The study explicitly states that sequencing was performed on plasma samples to analyze the virus in circulation.

Answer: Yes
"""

"""
Question: 2602

Evidence: The paper does not mention sequencing from PBMCs or proviral DNA.

Rationale: The entire methods and results sections focus on plasma virus sequencing. PBMCs are not mentioned.

Answer: No
"""

"""
Question: 2603

Evidence: PR-RT amplification and sequencing was successful for 154 of the 378 samples.

Rationale: This sentence provides the total number of plasma samples for which sequencing was successful.

Answer: 154
"""

"""
Question: 2604

Evidence: The paper does not mention sequencing from PBMCs.

Rationale: As PBMC sequencing was not performed, the number of such samples is zero.

Answer: 0
"""

"""
Question: 2605

Evidence: Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients... LLV was defined as a VL between 20 and 250 copies/ml.

Rationale: The study specifically selected patients with detectable viral load (LLV between 20-250 copies/ml), indicating active HIV replication was occurring at the time of sampling.

Answer: Yes
"""

"""
Question: 2606

Evidence: The paper does not mention sequencing from the proviral DNA reservoir.

Rationale: The study exclusively sequenced RNA from plasma virus, not DNA from integrated provirus in cells.

Answer: No
"""

"""
Question: 2701

Evidence: These 23 patients were all male with a median age of 48 years (IQR 43–54 years).

Rationale: The median age of the study participants was 48 years, which is adult. There is no mention of infants or children.

Answer: No
"""

"""
Question: 2702

Evidence: The paper does not describe the study as a clinical trial.

Rationale: The study is described as a retrospective observational study from a hospital cohort, not a clinical trial.

Answer: No
"""

"""
Question: 2703

Evidence: The paper does not describe the study as a clinical trial.

Rationale: Since the study was not a clinical trial, not all individuals were in one.

Answer: No
"""

"""
Question: 3101

Evidence: These 23 patients were all male with a median age of 48 years (IQR 43–54 years). Longitudinal samples were analysed over a median follow-up period of 4.7 years (IQR 3.3–5.7 years).

Rationale: The results section specifies that 23 patients were included in the final analysis for whom longitudinal samples were sequenced.

Answer: 23
"""

"""
Question: 3102

Evidence: To assess drug resistance during long-term follow-up, only patients with at least three genotyped longitudinal samples were included in further analysis (Table 1). These 23 patients...

Rationale: The paper states that the 23 patients included in the final analysis all had at least three samples successfully genotyped, meaning they all underwent HIV sequencing as part of the study.

Answer: Yes
"""

"""
Question: 4101

Evidence: Ten (43.5%) patients were drug-experienced before study inclusion.

Rationale: This statement implies that the remaining 56.5% (13 patients) were ART-naive prior to the study, as they are contrasted with the "drug-experienced" group.

Answer: Yes
"""

"""
Question: 4102

Evidence: Ten (43.5%) patients were drug-experienced before study inclusion.

Rationale: This sentence directly states that a portion of the patients had previously received ARV drugs.

Answer: Yes
"""

"""
Question: 4103

Evidence: Ten (43.5%) patients were drug-experienced before study inclusion.

Rationale: By stating that some patients were drug-experienced, it implies others were not (ART-naive), meaning the study includes sequences from both groups.

Answer: Yes
"""

"""
Question: 4104

Evidence: Ten (43.5%) patients were drug-experienced before study inclusion.

Rationale: If 10 out of 23 patients were drug-experienced, then 13 patients were ART-naive prior to the study. The number of *samples* from these naive individuals is not specified.

Answer: 13 individuals were ART-naive prior to the study. The number of samples from these individuals is not specified.
"""

"""
Question: 4105

Evidence: Changes in treatment regimen were frequent, only five patients (21.7%) remained on the initial regimen during the study period and nine patients (39.1%) switched or intensified ART more than twice.

Rationale: While the paper provides some information on ART changes during the study, it does not claim to provide a complete ART history for all individuals from the start of their infection. Table 1 only shows initial and final regimens.

Answer: No
"""

"""
Question: 4201

Evidence: The paper does not focus on or report the prevalence of transmitted HIV drug resistance in a population.

Rationale: The study's aim is to analyze resistance during long-term PLLV in patients on ART, not to measure the prevalence of transmitted resistance in a newly diagnosed cohort.

Answer: No
"""

"""
Question: 4202

Evidence: The paper does not focus on or report the prevalence of pretreatment HIV drug resistance in a population initiating therapy.

Rationale: The study analyzes resistance mutations that emerge during therapy in patients with PLLV. While baseline resistance was checked, the results are not presented as a prevalence estimate for a population starting treatment.

Answer: No
"""

"""
Question: 4301

Evidence: Twenty of these patients were on a boosted protease inhibitor (PI)-based regimen (87%). Single drug resistance mutations were detected in isolated samples of 4 patients, 2 of the 3 patients who initiated a non-nucleoside reverse transcriptase inhibitor- based regimen and 2 of the 20 on a PI-based regimen.

Rationale: The paper explicitly mentions patients receiving Protease Inhibitors (PIs) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). Table 1 also shows regimens containing NRTIs (e.g., TDF, ABC, 3TC).

Answer: Protease Inhibitors (PIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
"""

"""
Question: 4302

Evidence: The paper does not mention integrase inhibitors (INSTIs) being used by any patient.

Rationale: A review of the drug regimens listed in Table 1 and the main text shows no INSTIs (e.g., raltegravir, dolutegravir, elvitegravir) were part of the reported ART regimens.

Answer: No
"""

"""
Question: 4303

Evidence: Twenty of these patients were on a boosted protease inhibitor (PI)-based regimen (87%).

Rationale: This sentence directly states that the majority of patients received protease inhibitors.

Answer: Yes
"""

"""
Question: 4304

Evidence: Changes in treatment regimen were frequent, only five patients (21.7%) remained on the initial regimen during the study period.

Rationale: This clearly indicates that not all patients received the same ART regimen throughout the study.

Answer: No
"""

"""
Question: 4305

Evidence: The paper does not mention integrase inhibitors (INSTIs) being used by any patient.

Rationale: Since no INSTIs are reported in the treatment regimens, all individuals in the paper were INSTI-naive.

Answer: Yes
"""

"""
Question: 4403

Evidence: Changes in treatment regimen were frequent, only five patients (21.7%) remained on the initial regimen during the study period and nine patients (39.1%) switched or intensified ART more than twice.

Rationale: If only five patients remained on their initial regimen, then 18 patients (23-5) changed regimens at least once, meaning they received more than one ART regimen.

Answer: 18
"""

"""
Question: 4404

Evidence: ...nine patients (39.1%) switched or intensified ART more than twice.

Rationale: This sentence directly states the number of patients who had more than two treatment regimen changes (which implies receiving more than two distinct regimens).

Answer: 9
"""

"""
Question: 4405

Evidence: Changes in treatment regimen were frequent, only five patients (21.7%) remained on the initial regimen during the study period.

Rationale: This variation in the number of regimen changes means that not all individuals received the same number of ART regimens.

Answer: No
"""

"""
Question: 4406

Evidence: Changes in treatment regimen were frequent, only five patients (21.7%) remained on the initial regimen during the study period.

Rationale: Since only five patients remained on one regimen, the majority (18 patients) received more than one ART regimen.

Answer: No
"""

"""
Question: 4501

Evidence: The paper does not mention the drug dolutegravir.

Rationale: A search through the entire paper, including Table 1 which lists ART regimens, finds no reference to dolutegravir.

Answer: 0
"""

"""
Question: 4502

Evidence: Table 1 lists multiple patients with final or initial ART regimens containing DRV (darunavir), e.g., Patient 1: DRVr+TDF+FTC, Patient 2: DRVr+ABC+3TC.

Rationale: Table 1 provides a list of patients and their ART regimens, showing that several patients (e.g., 1, 2, 3, 6, 10, 13, 15, 16, 18, 19, 22, 23) were receiving darunavir (DRV). A precise count from the table confirms this.

Answer: 12
"""

"""
Question: 5101

Evidence: New DRM, not present at study initiation or in earlier samples, were found in four isolated samples from four different patients... Historical DRMs, detected before study initiation, were observed in three patients.

Rationale: For newly emerging mutations during the study, 4 individuals had DRMs. Additionally, 3 individuals had historical DRMs detected at baseline. Patient 13 is counted in both groups (historical and new DRM), so the total number of unique individuals with any DRM reported is 6 (Patients 1, 12, 13, 14, 19, 21).

Answer: 6
"""

"""
Question: 5102

Evidence: The paper does not mention integrase inhibitor (INSTI) resistance mutations.

Rationale: The study only sequenced the protease and reverse transcriptase genes, not the integrase gene. Therefore, no INSTI-resistance mutations could be reported.

Answer: 0
"""

"""
Question: 5103

Evidence: The paper does not specifically report TDF-resistance mutations like K65R.

Rationale: While the paper lists specific mutations found (e.g., K101E, M184V, I50L), none of them are known to be specifically associated with TDF resistance. The mutation K65R, a key TDF-resistance mutation, is not mentioned.

Answer: 0
"""

"""
Question: 5104

Evidence: The paper does not mention integrase inhibitor (INSTI) resistance mutations.

Rationale: As the integrase gene was not sequenced, no INSTI-resistance mutations are reported.

Answer: NA
"""

"""
Question: 6101

Evidence: The paper does not contain any mention of phenotypic susceptibility testing.

Rationale: The methods section only describes genotypic resistance testing through sequencing. No phenotypic assays are mentioned.

Answer: NA
"""

"""
Question: 6102

Evidence: The paper does not contain any mention of IC50 or IC90 values.

Rationale: The study is genotypic, not phenotypic, so it does not report inhibitory concentration values.

Answer: No
"""

"""
Question: 6103

Evidence: The paper does not contain any mention of IC50 fold change values.

Rationale: As no phenotypic testing was performed, fold change values are not reported.

Answer: No
"""

"""
"""
Question: 6104

Evidence: The paper does not contain any mention of phenotypic susceptibility testing.

Rationale: The entire methodology is based on genotypic sequencing of the HIV-1 PR and RT genes. No phenotypic susceptibility assay is described or used.

Answer: NA
"""

"""
Question: 6105

Evidence: The paper does not contain any mention of replication capacity.

Rationale: A thorough reading of the paper finds no discussion or analysis of viral replication capacity.

Answer: No
"""

"""
Question: 6106

Evidence: The paper does not contain any mention of phenotypic susceptibility testing.

Rationale: Since no phenotypic susceptibility testing was performed, no drugs were tested using such an assay.

Answer: NA
"""

"""
Question: 7101

Evidence: The paper does not mention site-directed mutagenesis.

Rationale: All viruses sequenced were obtained directly from patient plasma samples. The study did not involve the engineering of viruses through site-directed mutagenesis.

Answer: No
"""

"""
Question: 7102

Evidence: The paper does not contain any mention of in vitro passage experiments.

Rationale: As established for question 1103, the study was entirely based on clinical samples from patients and did not involve cultivating virus through in vitro passage.

Answer: No
"""